Dear customer, upon your request Ibrutinib Company were found the following resources. Our team makes effort to make you happy with the search on our site ninan.org

Patient Resources & Information for IMBRUVICA® (ibrutinib)

What is IMBRUVICA® (ibrutinib)? IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with: Mantle cell lymphoma (MCL) who have received at least one prior treatment; Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion…

Contact Us IMBRUVICA® (ibrutinib)

Find contact information for IMBRUVICA®. Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea.…

Ibrutinib Uses, Side Effects & Warnings - Drugs.com

Dec 03, 2019 · Ibrutinib is used to treat mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia, and small lymphocytic lymphoma.. Ibrutinib is also used to treat chronic graft-versus-host disease. Ibrutinib is usually given after …6.4/10…

Imbruvica 140 mg hard capsules - Summary of Product ...

Jan 16, 2020 · Ibrutinib was not carcinogenic in a 6-month study in the transgenic (Tg.rasH2) mouse at oral doses up to 2000 mg/kg/day with an exposure margin of approximately 23 (males) to 37 (females) times the human AUC of ibrutinib at a dose of 560 mg daily. Ibrutinib has no genotoxic properties when tested in bacteria, mammalian cells or in mice.95% CI (%): (58.0; 76.1)…

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved ...

Aug 02, 2017 · NORTH CHICAGO, Ill., Aug. 2, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of adult patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy. 1 With this approval, ……